Thilo J. Zander

MD. Medical Oncologist. Focused on innovative Lymphoma & Myeloma care. Opinions solely personal views.

[Eddie Cliff @Eddie_Cliff]

🚨 Hot off the press @NatRevClinOncol

In the wake of MajesTEC-9 presented at #ASCO26, we ask the provocative question: does cilta-cel have a future in myeloma?

https://t.co/ddjP5Xx4BC

What do you think?

#mmsm #myeloma #CARTcells @rajshekharucms @ManniMD1 @AlGarfall

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASCO26 @ASCO MajesTEC-9 @NEJM #mmsm

Teclistamab monotherapy vs PVd/Kd in RRMM with 1-3 prior lines (all lenalidomide + anti-CD38 exposed)
➡️Median follow-up: 17 months
➡️sCR 54% vs 9%
➡️18-mo PFS 70% vs 27% (HR 0.29)
➡️18-mo OS 79% vs 69% (HR 0.60)
➡️190/291 (~2/3) still on drug at cutoff
🛑Grade 3/4 infections in 42%.

https://t.co/475mG020cf

Exciting times
🧵

[Laura Korin @laura_korin]

Why do pts progress on epcoritamab? EPCORE NHL-1 paired biopsies
61% of progressors lost CD20: MS4A1 mut (58%) or transcriptional silencing (17%).
39% kept CD20 but lost intratumoral CD3+ T cells.
Antigen escape or T-cell failure: map the mechanism, choose the next tx. #EHA2026

[Thilo J. Zander @ThiloZander]

On Friday evenings after the stock market closes, the news that nobody is supposed to see come out.

LAG3 fail.

https://t.co/VKNesmdDIF

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: The U.S. FDA has granted accelerated approval for our foundational BCL2 inhibitor in relapsed/refractory mantle cell lymphoma — the first and only in R/R #MCL.

Full announcement: https://t.co/rr45qXXnzP

#Oncology #BeOneOnnovator

[Muzaffar Qazilbash @Transplant_Doc]

Making the case for ruxolitinib in CAR T-cell enterocolitis #bmtsm #mmsm @BloodPortfolio https://t.co/FjSqr82jof

[Vincent Rajkumar @VincentRK]

Updated mSMART guidelines for relapsed myeloma. This is a major revision. https://t.co/9SVglZ15Ce

1) First relapse: Options are BCMA CART, Tec-Dara, BCMA bispecific, or standard triplet. How to choose?
See below.

[Thilo J. Zander @ThiloZander]

@Blood_Cancers @DrJFriedberg @WilmotCancer if you neglect HD21 - just saying

[Thilo J. Zander @ThiloZander]

@davidasinclair Faster than expected by whom — the scientists raising their Series A?

[Thilo J. Zander @ThiloZander]

@davidasinclair Let’s wait for the randomized trials in humans. Everything else is hope and speculation.

[Thilo J. Zander @ThiloZander]

@davidasinclair Relax, man. Trump mindset makes you age faster – no matter what pills you take.

[Thilo J. Zander @ThiloZander]

Much ado about nothing. William Shakespeare @LuzernerZeitung

[Thilo J. Zander @ThiloZander]

https://t.co/c6bLA3OQml

[Thilo J. Zander @ThiloZander]

Dose-response study on exercise, sleep and nutrition for life expectancy. With 7 hours of sleep and 30 minutes of exercise per d, the entire potential benefit is achieved. Healthy food is of surprisingly little significance. Sleep and exercise surpass everything else. @TheLancet

[Raj Chakraborty @rajshekharucms]

MajesTEC-9 with both PFS and OS benefit of Teclistamab monotherapy versus PVD/Kd (in a population 100% Dara and Len-exposed)! We finally will have a great (non-CAR T) option for relapse post frontline Dara-(V)Rd, especially in patients relapsing on continuous Dara-R! Will there be a plateau similar to MajesTEC-3?
#mmsm

https://t.co/JQgKD1dwGZ

[Raj Chakraborty @rajshekharucms]

CARTITUDE-4 PFS & OS Update: 3-Year Follow-up! 5 key takeaways 🧵
#mmsm
https://t.co/9VjMEhiyhW

[Graham Collins @graham74GC]

Interesting. Concerned about using Len in every 1L DLBCL pt. Would imagine there would be significant excess tox. But let’s wait for publication. It’s a busy space - will tafa-len-RCHOP have what it takes to carve out a 1st line niche? #lymsm

[Thilo J. Zander @ThiloZander]

Tafasitamab + Lenalidomide + R-CHOP. Puh. Hope to see the results soon. Key question: Will CD-19 CAR-T still work for patients that relapse early after Tafa? I am not so sure. #DLBCL

[Hadja Lahbib @hadjalahbib]

Crans-Montana: EU-coordinated medical evacuations of burn patients from Switzerland are underway.

24 patients are being transferred to hospitals in Belgium, France, Germany and Italy, with transport supported by France, Italy, Luxembourg, Romania and Switzerland. 🧵

[Hamza Hashmi @hhashmi87]

#ASH25: Presented by @BeaRazzo @AlGarfall as poster but IMO as imp as any oral abstract #LimiTEC with Tec cessation after 6-9m for RRMM pts in VGPR+ led to 12m PFS ~65%
➡️n=50, 4 pLOT, 90% TCR, 20% w prior BCMA (ide-cel + BlenRep, 50% with no response to BCMA-DT!!)
➡️60% in CR prior to cessation of Tec, median fu 12m after cessation, 12m PFS 68%, OS 90%, PFS ⬆️in those w prior BCMA
➡️BCMA loss/mutation most likely mech of resistance but salvaged by Talq
💡Imp to see if B cell recovery a/w ⬇️hyogamm, ⬇️infections ��️IVIG⬆️QOL, #MMRF HORIZON study evaluating similar concept
💡Most PD occurred <6m post cessation, all those with PD <12m post cessation had no response to Tec; I wonder if we extend Tec cessation to only after 12m, it will identify pts who would benefit from reinitiation vs alt salvage
#MMSM